Page last updated: 2024-08-17

bromodeoxyuridine and Minimal Disease, Residual

bromodeoxyuridine has been researched along with Minimal Disease, Residual in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Boireau, S; Bouhya, S; Cartron, G; Ceballos, P; Hose, D; Klein, B; Moreaux, J; Requirand, G; Robert, N; Seckinger, A; Vincent, L	1

Other Studies

1 other study(ies) available for bromodeoxyuridine and Minimal Disease, Residual

Article	Year
BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma. Cytometry. Part B, Clinical cytometry, 2019, Volume: 96, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Cell Cycle; Cell Proliferation; Cohort Studies; Diagnosis, Differential; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Ki-67 Antigen; Lymphocyte Count; Male; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm, Residual; Plasma Cells; Prognosis; Progression-Free Survival; Recurrence; Staining and Labeling; Transplantation, Autologous	2019

Article

Year

BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.

Cytometry. Part B, Clinical cytometry, 2019, Volume: 96, Issue:3

Topics: Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Cell Cycle; Cell Proliferation; Cohort Studies; Diagnosis, Differential; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Ki-67 Antigen; Lymphocyte Count; Male; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm, Residual; Plasma Cells; Prognosis; Progression-Free Survival; Recurrence; Staining and Labeling; Transplantation, Autologous

2019